| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3873633 | The Journal of Urology | 2008 | 5 Pages |
Abstract
Analysis of these data suggests that choice of treatment for localized prostate cancer is unlikely to have a significant impact on response to phosphodiesterase type 5 inhibitors should they be needed after treatment. However, patients with better pretreatment sexual function are more likely to respond to phosphodiesterase type 5 inhibitors.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Irwin H. Lee, Natalia Sadetsky, Peter R. Carroll, Howard M. Sandler,